Insider Buying: Bolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Acquires $319,000.00 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) major shareholder Coastlands Capital Lp bought 50,000 shares of Bolt Biotherapeutics stock in a transaction dated Monday, November 9th. The shares were bought at an average price of $6.38 per share, for a total transaction of $319,000.00. Following the completion of the transaction, the insider directly owned 462,416 shares of the company’s stock, valued at $2,950,214.08. This represents a 12.12% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bolt Biotherapeutics Stock Up 0.9%

NASDAQ BOLT traded up $0.06 during trading on Tuesday, hitting $6.49. The stock had a trading volume of 11,797 shares, compared to its average volume of 92,139. Bolt Biotherapeutics, Inc. has a 12 month low of $3.10 and a 12 month high of $7.78. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. The company’s 50-day moving average price is $4.45 and its two-hundred day moving average price is $4.52. The company has a market capitalization of $12.50 million, a PE ratio of -0.39 and a beta of 0.85.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. As a group, sell-side analysts forecast that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $14.50.

Institutional Investors Weigh In On Bolt Biotherapeutics

A hedge fund recently bought a new position in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics makes up approximately 0.0% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 25th largest holding. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.